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1 Introduction
Biomedical research is a broad aspect of science
that looks for ways to prevent and treat diseases
that cause illness and death of people as well as
animals. It is an evolutionary process requiring care-
ful experimentation by many scientists, including
biologists and chemists. Discovery of new medi-
cines and therapies requires careful scientific exper-
imentation, development, and evaluation (New Jer-
sey Association for Biomedical Research, 2014). Ther-
apeutics refers to treatment and care of a patient
for the purpose of both preventing and combating
disease or alleviating pain or injury. In a broader
sense, it means, serving and caring for the patient
in a comprehensive manner, preventing disease as
well as managing specific problems (Rakel, 2014).
Biomedical research is conducted in pharmaceuti-
cal, biotechnology and medical device firms. The
paper addresses the therapeutic segments in the
pharmaceutical industry, not all biomedical indus-
tries. Reducing the disease burden of the popula-
tion has emerged as a major development chal-
lenge in several developing countries. R&D has
always been the backbone and the underlying
strength of biomedical innovation in the pharma-
ceutical industry. In the past decades, the Indian
pharmaceutical industry has delivered multiple
life-saving medicines contributing to new treat-
ment options for several biomedical needs. Cur-
rently, it is playing a major role in medical needs
and R&D investments in neuroscience, cardiovas-
cular, endocrine, gastrointestinal, respiratory and
genitourinary research. 
The Indian pharmaceutical industry was valued
at US$ 12 billion in the year 2013. Globally, India
ranks 3rd in terms of volume and 14th in terms of
value (Business Standard, 2014). The top 10 thera-
py areas (anti-infective, cardiac, gastrointestinal,
respiratory, pain/analgesics, vitamins/nutrients,
anti-diabetic, gynecology, central nervous system
and derma) of the Indian pharmaceutical contribute
to approximately 90% of the Indian pharmaceuti-
cal sales. The contribution of chronic therapies to
the Indian pharmaceutical industry has raised from
27% in 2010 to 30% in 2013. Chronic therapies (car-
dio, gastro, central nervous system and anti-dia-
betic) have outperformed the market for the past
four years and are growing at a rate of 14%, faster
than the acute therapies (anti-infective, respirato-
ry, pain and gynecology) which grew at 9.6% (PWC,
2013). Within the domestic formulations market
the major therapeutic categories are anti-infective,
gastrointestinal, cardiac, gynecology and derma-
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tology. The leading drug classes were Cephalosporin,
anti‐peptic ulcers, oral anti‐diabetic and Ampicillin
or Amoxycillin, etc. (DOP, 2013). 
In this backdrop, the present paper is an attempt
to analyze the biomedical R&D in the therapeutic
drug industry in India. The paper is divided into six
sections. Section one deals with the introduction
and the current market scenario of biomedical
industry in therapeutic segments. Section two deals
with the methods used for data collection. The third
section presents the factors influencing growth of
biomedical industry. Section four presents Indian
biomedical firms in the therapeutic segments, and
section five deals with the role of public sector units
and research institutes in the biomedical R&D. Final-
ly, section six deals with discussion and conclusion. 
2 Research method
The research study is based on a quantitative
research method. A quantitative method is gener-
ally used in order to collect statistical data and con-
duct statistical analyses (Yin, 2003). In this paper,
quantitative indicators for R&D expenditure, net
sales, profits, market share and registered patents
have been collected. Details of R&D and innova-
tion activities of Indian pharmaceutical firms, par-
ticularly in the therapeutic segments, were picked
out through various sources such as authentic inter-
net resources, annual reports, newspaper clippings,
websites, etc. Data is mainly collected from com-
panies’ websites and annual reports: www.lupin.
com, www.sunpharma.com, www.cipla.com,
www.zyduscadila.com, www.torrentpharma.com
and www.ipcalabs.com. We also analyzed these
facts from the peer-reviewed literature and books
published by academia. 
We have chosen the six largest Indian pharma-
ceutical companies in terms of revenue from world-
wide pharmaceutical sales in therapeutic segments:
Lupin, Sun Pharma, Cipla, Zydus Cadila, Torrent Phar-
ma, and Ipca. These leading Indian companies exam-
ined here have been selected on the following basis:  
They are highly profitable and fast growing.
Their initial technical skills have been in 
chemistry and low cost manufacturing.
These companies are mainly active in the 
generics sector and produce generics to be sold 
in India.
They have significant levels of international 
business, including products on sale in the 
highly regulated markets in the western 
countries. They obtain approval for and 
market generic drugs in the USA and Europe. 
They develop in-house skills in drug discovery 
and developing new patented drugs including 
biopharmaceuticals.
These six companies have diverse roots. Some
were founded many years ago, e.g. Cipla in 1935,
Zydus Cadilla in 1952, Torrent Pharma in 1959, Lupin
in 1968 and some comparatively recently, e.g. Ipca
in 1976, 1983 Sun Pharma in 1983. The vision of these
companies is to make India self-sufficient in health-
care, a leader in the pharmaceutical industry, deliv-
er world class products and services, and make qual-
ity medicine more accessible and affordable to the
common man globally.
3 Factors influencing growth of biomed-
ical industry
3.1 Growing and ageing population
The current world population of 7.2 billion is
projected to increase by over 1 billion in the next 12
years and reach 9.6 billion by 2050 (UN News, 2013).
Between 2000 and 2050, the proportion of the
world's population over 60 years will double from
about 11% to 22%. The absolute number of people
aged over 60 years is expected to increase from
605 million to 2 billion over the same period (WHO,
2014a). Most of the older people die of non-com-
municable diseases such as heart disease, cancer
and diabetes, rather than from infectious and par-
asitic diseases. The growing ageing population will
drive the demand for medicines and increase phar-
maceutical spending.
3.2 Changing lifestyle
Rising prevalence of lifestyle diseases like hyper-
tension, diabetes mellitus, dyslipidaemia and over-
weight or obesity are the major risk factors for the
development of cardiovascular diseases. Cardio-
vascular diseases (CVD) continue to be the major
cause of mortality representing about 30% of all
deaths worldwide (Pappachan, 2011). With rapid
economic development and increasing western-
ization of lifestyle in the past few decades, preva-
lence of these diseases have reached alarming pro-
portions among Indians in the recent years (Pap-
pachan, 2011).
3.3 The rising incidence of non-communicable dis-
eases
Non-communicable diseases are the top cause
of death worldwide, killing more than 36 million
people in 2008. Cardiovascular diseases were
responsible for 48% of these deaths, cancer 21%,
chronic respiratory diseases 12%, and diabetes 3%
(WHO, 2014b). World Health Organization (WHO)
forecasts that by 2020, the non-communicable dis-
eases will account for 44 million deaths a year,
increasing by 15% from 2010 (WHO, 2010).
3.4 Prevalence of communicable diseases
Although disease patterns change constantly,
communicable diseases remain the leading cause
of mortality and morbidity in less developed coun-
tries. According to WHO, low-income countries cur-
rently have a relatively high share of deaths from:
(i) HIV infection, tuberculosis and malaria, (ii) other
infectious diseases, and (iii) maternal, perinatal and
nutritional causes compared with high and mid-
dle income countries (Gupta and Guin, 2010; WHO,
2004).
3.5 Rising spend on healthcare
The healthcare sector in India is expected to
grow at a CAGR of 15% and touch US$ 158.2 billion
in 2017 from US$ 78.6 billion in 2012 (IBEF, 2014a).
India is a country with a growing population, its
per capita healthcare expenditure has increased
at a CAGR of 10.3% from US$ 43.1 in 2008 to US$
57.9 in 2011, and going forward it is expected to
reach US$ 88.7 by 2015 (IBEF, 2014a). The factors
behind the growth of the sector are rising incomes,
easier access to high quality healthcare facilities
and greater awareness of personal health and
hygiene.
3.6 Growth in healthcare financing products
Development in the Indian financial industry
has eased healthcare financing with the introduc-
tion of products such as health insurance policy,
life insurance policy and cashless claims. This has
resulted in an increase in healthcare spending,
which in turn, has benefitted the pharmaceutical
industry.
3.7 Health insurance is growing
Health insurance in India is a growing segment
of India’s economy. It is expected to grow at a CAGR
of 15% over the next five years and nearly 650 mil-
lion people will enjoy health insurance coverage.
Around 80% healthcare is financed out of pocket
(PWC, 2010). The private healthcare facilities grew
rapidly and insurance coverage increased. The small
percentage of Indian who has some insurance and
government run insurance company is the main
provider. The government sponsored programmes
largely focused on the below poverty line (BPL) seg-
ment and are expected to provide coverage to near-
ly 380 million people by 2020 (Bhadoria et al., 2012).
3.8 Increase in domestic demand
More than half of India‘s population does not
have access to advanced medical services and is
mainly depending on traditional medicine prac-
tices. However, with the increase in awareness lev-
els, rising per capita income, change in lifestyle due
to urbanization and increase in literacy levels,
demand for advanced medical treatment is expect-
ed to rise. Moreover, growth in the middle class
population would further influence demand for
pharmaceutical products.
3.9 Rise in outsourcing activities
Increase in the outsourcing business in India
would accelerate the growth of Indian pharmaceu-
tical industry. Some of the factors that are likely to
influence clinical data management and bio-sta-
tistics markets in India in the near future include:
1) cost efficient research 2) highly-skilled labour
base 3) cheaper or low cost of skilled labour 4) pres-
ence in end-to-end solutions across the drug-devel-
opment spectrum and 5) robust growth in the IT
industry.
3.10 High R&D expenditures
The government of India is committed to sup-
porting the expansion of R&D in the pharmaceu-
tical and biotechnology industries and has taken
a direct role in funding R&D in both, public and pri-
vate sectors. The total biomedical R&D expendi-
ture by both public and private sectors was US$
10.4 billion between the year 2007 and 2012 in India
(Chakma et al., 2014). This R&D expenditure includ-
ed expenditures by government agencies, educa-
tional or research institutions, and charitable organ-
izations, whereas for the industries it included
expenditures by biotechnology, medical-device, and
pharmaceutical firms.
4 Indian biomedical firms in therapeutic
segments
4.1 Overview of the major players
Biomedical innovation in the pharmaceutical
industry in India is one of the largest and most
advanced among the developing countries. The
industry produces an entire range of products
belonging to all major therapeutic segments. In
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Table 1 The six selected pharma companies by net sales, profits, growth rates and market share in 2013-14 (Source: 
Authors’ compilation based on each company’s annual report). 
the pharmaceutical world, India’s opportunities are
significant in the context of medicinal develop-
ment in the 21st century (Kumar and Satish, 2007).
India has an existing generic based drug industry
with an increasing focus on discovery. Antibiotic,
cardiovascular, analgesic and antipyretic, antacids
and anti-ulcerants, respiratory and anti-tuberculo-
sis are the major therapeutic segments which
account for over 90% of the domestic formulation
market (Kumar and Satish, 2007). Other important
therapeutic segments are anti-parasitic and anti-
fungal products, non-steroidal anti-inflammatory
drugs (NSAID) drugs, anti-anaemic, anti-diabetes,
anti-malarial, anti-tuberculosis, central nervous
system (CNS) and psychiatric products, gynaecol-
ogy, nutrients and mineral supplements. Table 1
presents the figures of the six selected Indian phar-
maceutical companies revealing their net sales,
profit, growth rates and market share during the
financial year 2013-14.
Sun Pharma has the largest share and has a
strong positioning in chronic segments like central
nervous system (CNS), cardiovascular and diabetol-
ogy, together accounting for more than 50% of
India formulation revenues. Torrent Pharma post-
ed the highest growth in revenue; growth was pri-
marily driven by cardiology, diabetology, CNS in
chronic and gastroenterology in acute segments.
The company is ranked number four in cardiovas-
cular segment and in neuro-psychiatry therapies. 
Lupin is one of the fastest growing players in
high growth therapy segments like cardiology, cen-
tral nervous system, diabetology, anti-asthma, and
gynaecology, anti-infective, gastro intestinal and
oncology. The company is the second largest play-
er in India’s respiratory (anti-asthma) segment,
third largest player in the cardiovascular segment
and seventh largest player in diabetes segment.
Cipla holds the second largest share and it has a
leading position in various therapeutic categories,
including respiratory and urology, and reinforces
the potential to strengthen its presence in India
across other therapies. It continues to increase its
focus on CNS, oncology, dermatology and gastroen-
terology. The company holds a dominant position
in the respiratory therapy segment and grasps 70%
market share in this segment. 
Zydus Cadila is one of the largest market play-
ers with leading positions in key therapy areas. It
has strong leadership positions in the represent-
ed markets of cardiology, gynaecology, gastroin-
testinal and respiratory therapy areas. The compa-
ny has gained second position in the dermatology
segment and shifted from the sixth rank in 2013 to
the fourth rank in 2014. Ipca is a therapy leader in
India for anti-malarial and it focuses on chronic
therapy segments such as cardiovascular, anti-dia-
betics and non-steroidal anti-inflammatory drugs
(NSAID)
4.2 Investments into R&D 
The pharmaceutical industry is knowledge inten-
sive and R&D investment plays a crucial role in the
growth of this industry (Shah et al., 2010). R&D in
pharmaceutical industry includes directional search
solutions to existing medical problems and unmet
medical requirements. The pharmaceutical R&D
may be concentrated in the New Chemical Entities
(NCE), Novel Drug Delivery Systems (NDDS) or in
generic products. R&D is a comparatively recent
phenomenon for Indian pharmaceutical firms which
gained momentum only after the year 1995. India
introduced the product patent regime in accor-
dance with the Trade Related Aspects of Intellec-
tual Property Rights (TRIPs) agreement, in January
Company Net sales(US$ in million)
Profits
(US$ in million)
Growth rates 
(%)
Market share
(%)
Lupin 1,733 287 17 2.8
Sun Pharma 2,503 501 30 5.4
Cipla 1,579 333 22 5.3
Zydus Cadila 385 126 17 4.4
Torrent Pharma 503 119 30 4.2
Ipca 509 75 16 2.0
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2005 with an amendment to the patent act. The
allowance of product patents supported the con-
fidence of innovator pharmaceutical companies in
the Indian market (IBEF, 2014b). The cumulative fig-
ure for the top 30 companies is about US$ 837.9
million in 2012-13. This works out to be about 7.8%
of the net sales of these companies (Rao, 2014). Fig-
ure 1 shows the R&D expenditures of selected phar-
maceutical companies over the past five years. 
The R&D expenditure of these pharma compa-
nies has steadily increased. In the financial year
2013-14, the total R&D expenditure by these six
pharmaceutical companies was US$ 460.70 mil-
lion. Currently, Lupin is the top pharma company
spending for its R&D in the biomedical innovation
in India. The company invested 8.6% of its net sales
in R&D and related expenditure amounting to US$
149.80 million in the financial year 2014. The com-
pany Novel Drug Discovery and Development
(NDDD) program focuses on the discovery, devel-
opment and commercialization of new drugs for
new therapies and various diseases that include
metabolic and endocrine disorders, pain and inflam-
mation, autoimmune diseases, CNS disorders, can-
cer and infectious diseases. The R&D of Sun Phar-
ma in India focuses on the chronic segments like
diabetes, central nervous system, hypertension etc.
The company spends around 6% of its net sales in
the R&D, and has four modern R&D centres, expert
scientist teams who are engaged in complex devel-
opmental research projects in process chemistry
and dosage forms, including complex generics based
on drug delivery systems.
The R&D wing of Cipla is involved in the devel-
opment of new drug formulations for existing and
new active drug substances, novel drug delivery
system (NDDS) and development of products relat-
ed to the indigenous systems of medicines. The
total R&D expenditure as a percentage of total
turnover was around 5% during the financial year
2014. The R&D of the company focuses on various
therapeutic segments like respiratory, anti-viral,
gynaecology and urology. Zydus Cadila focused on
finding innovative therapies for diseases affecting
mankind through continuous R&D. The total R&D
expenditure as a percentage of total turnover was
around 11% during the financial year 2014. The major
areas of R&D include new chemical entities (meta-
bolic disorders, diabetes, obesity, dyslipidaemia,
inflammation and pain, rheumatoid arthritis, bac-
Figure 1 R&D expenditures of selected Indian pharmaceutical companies between 2010 and 2014 (Source: Authors’ 
compilation based on each company’s annual report).
160
0
60
40
20
80
100
120
140
2009-10
2010-11
2011-12
2012-13
2013-14
US$ in million
Lupin Sun Pharma Cipla
Zydus 
Cadila
Torrent 
Pharma Ipca
Azamat Ali and Kunal Sinha
Journal of Business Chemistry 2015, 12 (3)© 2015 Institute of Business Administration 110
terial infections, and cancer) research, formulation
development, process research and novel drug deliv-
ery system. 
Torrent Pharma is currently working on sever-
al in-house new chemical entities R&D projects
within the areas of diabetes and its related com-
plications, metabolic, cardiovascular and respira-
tory disorders. The total R&D expenditure as a per-
centage of turnover was 4.26% during the finan-
cial year 2014. The company R&D expenses have
increased by 10% to US$ 21.57 million as compared
to US$ 19.54 million during the financial year 2013.
Product development costs accounted for 71% and
discovery research costs accounted for 29% in 2014
of the total R&D cost. The company has expert sci-
entist teams who offer dedicated services in the
areas of discovery research, generic drug develop-
ment, new drug delivery systems and value added
generics thereby transforming discoveries into the
highest quality therapeutic products. Ipca is a ther-
apy leader in India for anti-malarial and also leads
in DMARDs (Disease Modifying Anti-Rheumatic
Drugs) treatment for rheumatoid arthritis. The com-
pany carries out R&D in several areas including the
development of newer dosage forms and new drug
delivery systems, process improvements, technol-
ogy absorption and optimization of basic drugs,
process simplification, etc. The company had stepped
up its R&D expenditure from US$ 15.69 million in
the financial year 2013 to US$ 19.2 million in the
year under report. The total R&D expenditure as a
percentage of total turnover is 3.87% during the
financial year 2014. Table 2 shows the disease wise
product specific R&D activities of the selected phar-
maceutical companies in India.
The table shows the categorization of diseases
into type I, II, and III and product wise specific R&D
activities of selected companies during 2002 to
2011. This indicates that Ipca Lab and Lupin Ltd are
more active in type I and type II diseases. Sun Phar-
ma and Zydus Cadila are more active in type I dis-
eases. In case of Cipla and Torrent Pharma are less
R&D activities compared to other companies. 
Table 2 Disease wise product specific R&D activities of companies active in India between 2002 and 2011, whereby 1-15 
present the number of disease wise products (adapted from NHSRC Report, 2013).
2002-2004 2005-2007 2008-2011 Total
Disease type1
I II III I II III I II III
Com-
panies
Lupin
Ltd 1 4 4 4 1 14
Sun
Pharma 2 7 9
Cipla Ltd 1 1 2
Zydus
Cadila 3 1 9 13
Torrent
Pharma 1 1
Ipca Lab 4 1 5 5 15
Grand
total 1 13 6 26 6 2 54
1) Type I: Diabetes, cancer, metabolic diseases, hepatitis, influenza, cardiovascular, infectious diseases, inflammatory  
diseases, allergy, respiratory diseases. Type II: HIV/AIDS, tuberculosis, and malaria. Type III: Leishmaniasis, lymphatic 
filariasis, leprosy, diarrhoea (neglected diseases of the poor in developing world).
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4.3 Therapeutic areas of new drug R&D
Research in the development of drugs has gen-
erally two major aspects: (i) discovery of a new drug
molecule, and (ii) invention of new formulations
of drugs with higher therapeutic index (Maitra,
2000). A drug discovery pipeline has various phas-
es that can be grouped into four stages: discovery,
pre-clinical, clinical trials and marketing (or post
approval). It is an important indicator of the value
and future prospects of a company. Usually, the
more compounds in the pipeline and the more
advanced stage these are in, the better. Table 3
includes a list of new molecules of selected lead-
ing pharmaceutical companies in the therapeutic
segment in India which are at different stages of
development.
The table shows that R&D efforts focus on chron-
ic disease such as diabetes. Lupin’s Novel Drug Dis-
covery and Development (NDDD) program focus-
es on the discovery, development and commercial-
ization of new drugs that address disease areas
with significant unmet medical needs. Currently,
the program in the CNS area completed phase I
studies in Europe and is being advanced to Phase
II clinical trials in Europe. Cipla R&D is focused
towards developing new products, improving exist-
ing products as well as drug delivery systems and
expanding product applications. Cipla and the Drugs
for Neglected Diseases initiative (DNDi) are devel-
oping a more acceptable granule formulation of
40/10 mg lopinavir/ritonavir as part of a first-line
regimen for infants and young children.
The Sun Pharma strategy has been dominating
the lifestyle disease segments. SUN-597 is a topi-
cal glucocorticoid being developed for allergic rhini-
tis, inflammation, asthma and other applications
and completed its Phase I clinical trials in India.
SUN-L731 is being developed as an oral LTD4 antag-
onist for treatment of Asthma & Allergic Rhinitis.
SUN-K706 is a novel tyrosine kinase inhibitor (TKI),
intended for the treatment of chronic myeloge-
nous leukaemia (CML). Currently, available oral
drugs like Imatinib (Gleevec®), Nilotinib (Tasigna®)
and Dasatinib (Sprycel®) are quite effective
chemotherapeutic agents CML. Sun 09 is a pro-
drug of Baclofen and is being developed as an effi-
cient Baclofen. Baclofen is the standard drug of
choice for the treatment of spasticity. Zydus Cadi-
la currently conducts basic new drug discovery
research in cardio-metabolic, inflammation, pain
and oncology therapeutic areas. During the year
2014, the company launched Lipaglyn (Saroglitazar)
in India, its first NCE for treating diabetic dyslipi-
daemia and hypertriglyceridemia. It is the first drug
discovered and developed indigenously by an Indi-
an pharmaceutical company. 
Torrent Pharma R&D is engaged in the discov-
ery of new chemical entities and the development
of new processes and suitable formulations for
known Active Pharmaceutical Ingredients (APIs).
The most advanced discovery program of the Com-
pany is Advanced Glycation End-Products (AGE)
Breaker, of which the Phase II clinical trials for the
indication of diabetes associated heart failure in
India and Europe is completed. Ipca is actively
engaged in the segment of new Drug Discovery
Development by collaborating with various research
organizations and premier institutes in India and
abroad. The company’s current pipeline includes
pain management, anti-ulcer and anti-malarial and
one of the novel molecules (CDRI- 97/78) has shown
very promising anti-malarial activity and is current-
ly in clinical Phase-I in India. 
4.4 R&D outcomes
R&D investments are indicators for the main
inputs into science based innovation. Publication
and patent data provide complementary indica-
tors for research and development activities,
although capturing intermediate outputs (OECD,
2008). Patents are the most important way in which
researchers can protect the ideas or technologies
they have developed. It reflects the ability of trans-
ferring scientific results into technological appli-
cations. It is also essential for economic exploita-
tion of research results and is thus central to any
analysis which deals with economic potentials of
technology and the identification of the most prom-
ising fields and actors in terms of persons, organ-
izations or countries (Hullmann, 2006; Ali and Sinha,
2014). Figure 2 provides company wise patent appli-
cations filed and granted at different patent offices
(Indian Patent Office (IPO), European (EPO) and
United States Patent and Trade Office (USPTO)).
The figure shows that Sun pharma has the max-
imum number of patents granted. Lupin has com-
parably filed the highest number of patent appli-
cations in India and other countries. This included
108 formulation patents, 39 Active Pharmaceuti-
cal Ingredients (APIs) or process patents, 2 biotech
and 232 new chemical entity (NCE) patents in India
and other countries. Cipla has been granted about
100 patents. Patent filing includes drug substances,
drug products, platform technologies, IP on poly-
morphs and crystallinity, and medical devices. Zydus
Cadila has filed over 115 patents in the US, Europe
and other countries, taking the cumulative num-
ber of filings to over 1,075. Torrent pharma has 818
patents filed for novel drug delivery systems (NDDS)
technology, drug discovery projects and innovative
process of API and formulations for various geog-
raphies and 315 have been granted so far. Ipca has
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Table 3 Drug development pipelines of selected Indian pharmaceutical companies (Source: Authors’ compilation based on 
each company’s annual report).
Company Identifier/molecule description Therapeutic area
Stage of
development
Lupin Central Nervous System (CNS) Phase II
Sun 
Pharma
Sun-597 Allergic rhinitis, inflammation, asthma Phase I
Sun-L731 Asthma and allergic rhinitis Preclinical
Sun-K706 Chronic Myelogenous Leukaemia (CML) Preclinical
Sun-1334H Allergic diseases Phase II
Sun-09 Spasticity Phase I
Sun-44 Neuropathic pain Preclinical
Cipla/
DNDi
Boosted PI Lopinavir/ritonavir (LPV/rtv) Phase I
Boosted PI/2NRTIs LPV/rtv/ abacavir (ABC) or zidovudine (AZT)/lamivudine (3TC) (4-in-1) Phase I
Zydus 
Cadila
PPAR alpha; gamma Treatment of hypertriglyceridemia NDA
PPAR alpha Dyslipidaemia Phase II
GPR-119 agonist Diabetes Phase I
Long acting DPP-IV Diabetes Phase I
PEG-EPO Anaemia of chronic renal failure Phase I
Rabies MAb Rabies Phase I
Torrent 
Pharma
AGE-Breaker (TRC4186) Diabetes Phase II
T2 Mimetic Cardio metabolic risk Phase I
DARA Anti-hypertensive Lead optimization
HIF (TRC 160334) Acute kidney injury Lead optimization
Diabetes Lead optimization
Chronic obstructive pulmonary disease (COPD) Early discovery
Ipca Novel molecule CDRI-97/78 Anti-malarial Phase I
Azamat Ali and Kunal Sinha
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Figure 2 Number of filed and granted patents for the selected companies until 31 May 2014 (Source: Authors’ compilation 
based on each company’s annual report).
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220 patent applications filed till date in India, USA
and other countries. These applications relate to
novel and innovative manufacturing processes for
the manufacture of APIs and pharmaceutical for-
mulations.
5 Role of public sector units and research
institutes
There are five central public sector companies
established by the government of India, which are
Indian Drugs and Pharmaceuticals Limited (IDPL),
Hindustan Antibiotics Limited (HAL), Bengal Chem-
icals and Pharmaceuticals Limited (BCPL), Bengal
Immunity Limited (BIL) and Smith Stanistreet Phar-
maceuticals Limited (SSPL). HAL and IDPL play a
very important role in the biomedical R&D in India.
HAL is the first public sector company in drugs and
pharmaceuticals and HAL was incorporated on 30th
March, 1954 in Pune.  It was established to produce
antibiotic with the assistance of WHO and UNICEF.
It is the first company in India to manufacture of
antibiotic drugs like penicillin, ampicillin, gentam-
icin, streptomycin, sulphate, anhydrous from the
basic stage (Mazumdar, 2013). IDPL was incorporat-
ed on 5th April, 1961 for achieving India’s march
towards self-sufficiency and self-reliance in the
field of drugs and pharmaceuticals, particularly
with the primary objective of creating self-suffi-
ciency in essential lifesaving drugs and medicines
(DOP, 2012).  Presently, under different classes of
therapeutic medicines, around 87 generic or brand-
ed drugs covering tablets, capsules, injections, vita-
mins, oral rehydration solution (ORS) pouches etc.
are being manufactured in various plants of IDPL
(DOP, 2012).
The publicly funded research institutes are also
playing a key role in the growth of the biomedical
sector in India. The government of India has creat-
ed a number of research institutes under the guid-
ance of the Indian Council of Medical Research
(ICMR) and the Council of Scientific and Industrial
Research (CSIR) to promote technological advance-
ment of the country. The CSIR institutes are play-
ing a significant role in boosting up the knowledge
base in the biomedical R&D sector of India. The
technologies developed by the public research insti-
tutes are also transferred effectively from labora-
tories to industries. The success of the CSIR labo-
ratories in fostering the technological environment
of the Indian pharmaceutical firms in the biomed-
ical sector is also evident and shows that almost
all the top pharmaceutical companies like Lupin,
Ranbaxy, Cipla, Nicholas Primal, Wockhardt, Tor-
rent Pharma, Sun Pharmaceutical, Orchid, and
Aurobindo Pharma Ltd have benefited from the
services of the research institutes in India in some
or the other way. Table 4 shows some of the pub-
lic research pharmaceutical R&D Institutes in India. 
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6 Conclusion 
The Indian biomedical industry has been on a
strong growth trajectory in the last decade. It has
achieved several milestones and is well positioned
to leverage emerging opportunities. The industry
needs to tackle various issues related to its opera-
tions and regulations. The current Indian drug dis-
covery pipeline offers attractive opportunities, as
it illustrates that Indian pharma companies have
proven their capability to build integrated drug dis-
covery capabilities, and to drive molecules from the
early discovery stage to development. 
The analysis of R&D expenditures of pharma-
ceutical firms shows that there had been a growth
in the R&D intensity. Presently, most of the com-
pany’s drug development pipeline is in the stages
of lead identification, preclinical research and Phase
I. In the R&D for new drugs, the analysis of the new
drug pipelines of leading Indian pharma firms shows
that the new patent regime has not been able to
become the driving force. The R&D activities of Indi-
an firms are increasingly getting concentrated on
lifestyle diseases of global nature and they do not
find any opportunity in local diseases such as tuber-
culosis and malaria except a single pharma com-
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pany, i.e. Ipca laboratory. The patenting activity is
focused on new processes, new dosage forms and
drug delivery systems.  
There is a need for real prioritization of R&D
and innovation activities by the government. The
public sector companies and public sector labora-
tories have played a major role in augmenting the
science and technology skills of the private sector
industry. The discovery and development of new
drugs are the result of a close collaboration between
university and industry researchers. In this process,
the public and private sectors pursue distinct but
complementary objectives. Whereas the role of the
public sector is centred on deepening our basic
understanding of disease, that of the private sec-
tor is more focused on applied research aimed at
converting this knowledge into effective treat-
ments. Public research institutions play an impor-
tant role in the system’s positive evolution but they
are dependent on the government policy and budg-
et. The benefits that flow from public subsidies to
university research can be reaped only once effec-
tive treatments have been developed – only the
pharmaceutical industry is in the position to play
this role. 
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Table 4 Public research pharmaceutical R&D institutes in India (Source: Authors’ Compilation).
Institutes
National Institute of Pharmaceutical Education and Research (NIPER)
Indian Institute of Chemical Technology (IICT)
Centre for Cell & Molecular Biology (CCMB)
Indian Institute of Chemical Biology (IICB)
Indian Toxicology Research Institute (ITRI)
Institute of Genomic and Integrated Biology (IGIB)
National Institute of Immunology (NII)
Indian Institute of Science (IISc)
National centre for Biological Sciences (NCBS)
National Chemical Laboratory (NCL)
Institute of Microbial Technology (IMTECH)
Central Drug Research Institute (CDRI)
Regional Research Laboratories (RRL)
Azamat Ali and Kunal Sinha
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